ASH 2025 | Where is ALL therapy moving based on ASH 2025 abstracts?
In this video, Marlise Luskin, MD, MSCE, Dana-Farber Cancer Institute, Boston, MA, briefly discusses where the field of acute lymphoblastic leukemia (ALL) is moving based on recent data and presentations at the ASH 2025 meeting, noting that treatment is improving due to advances in therapies in both the first-line and relapsed settings. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
I think overall, B-ALL, a refrain I hear commonly is that this is becoming a more satisfying disease to treat, because when we meet a patient we know that we have better therapies for both first-line and relapse therapy than we did even just a few years ago and that we’re seeing presentations to suggest that we’re going to continue to see advances in the coming years...
I think overall, B-ALL, a refrain I hear commonly is that this is becoming a more satisfying disease to treat, because when we meet a patient we know that we have better therapies for both first-line and relapse therapy than we did even just a few years ago and that we’re seeing presentations to suggest that we’re going to continue to see advances in the coming years. It’s challenging because every couple of years the messaging for the patients is different, but that’s a good problem to have. I would say the theme of the abstracts this year’s ASH are increasing understanding about the best place for novel therapies, immunotherapies. Blinatumomab, inotuzumab originally approved for the relapsed setting, now increasingly incorporated in the frontline setting. And cellular therapy, such as CAR T-cells, approved for relapsed setting, being investigated in the frontline setting. So we’re trying to get better understanding of how to incorporate all of our available therapeutics to cure more patients. And when possible, de-escalate chemotherapy, appropriately restrict transplantation to those that need it. And so we’re getting incremental data every year about how different subgroups respond and how to best treat them.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
